John Libbey Eurotext

Hématologie

MENU

Consensus français sur les syndromes myélodysplasiques et la leucémie myélomonocytaire chronique : diagnostic, classifications, traitement Mise à jour 2015 par le Groupe francophone des myélodysplasies (GFM) Volume 21, issue 1, Janvier-Février 2015

Figures

  • Figure 1
  • Figure 2
  • Figure 3

Tables

Authors
* Reprint
a Coordinator

MDS are clonal pluripotent, stem cell disorders characterized by ineffective hematopoiesis resulting in blood cytopenias contrasting with a typically cellular marrow. MDS evolve frequently to acute myeloid leukemia (AML), and are the most frequent preleukemic states in adults.MDS predominate in the elderly, with a median age at diagnosis of about 70 years. Their incidence is 4 to 5 per 100,000 persons per year. Their etiology is generally unknown. In 15 to 20% of cases, however, MDS are secondary [...]